Back to Search Start Over

Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

Authors :
Bioquímica y biología molecular
Biokimika eta biologia molekularra
Araujo, Angela M.
Abaurrea, Andrea
Azcoaga, Peio
López Velazco, Joanna I.
Manzano, Sara
Rodríguez Martínez, Javier
Rezola, Ricardo
Egia Mendikute, Leire
Valdés Mora, Fátima
Flores, Juana M.
Jenkins, Liam
Pulido, Laura
Osorio Querejeta, Iñaki
Fernández Nogueira, Patricia
Ferrari, Nicola
Viera, Cristina
Martín Martín, Natalia
Tzankov, Alexandar
Eppenberger Castori, Serenella
Álvarez López, Isabel
Urruticoechea, Ander
Bragado, Paloma
Coleman, Nicholas
Palazón, Asís
Carracedo Pérez, Arkaitz
Gallego Ortega, David
Calvo González, Fernando
Isacke, Clare M.
Caffarel, María M.
Lawrie, Charles
Bioquímica y biología molecular
Biokimika eta biologia molekularra
Araujo, Angela M.
Abaurrea, Andrea
Azcoaga, Peio
López Velazco, Joanna I.
Manzano, Sara
Rodríguez Martínez, Javier
Rezola, Ricardo
Egia Mendikute, Leire
Valdés Mora, Fátima
Flores, Juana M.
Jenkins, Liam
Pulido, Laura
Osorio Querejeta, Iñaki
Fernández Nogueira, Patricia
Ferrari, Nicola
Viera, Cristina
Martín Martín, Natalia
Tzankov, Alexandar
Eppenberger Castori, Serenella
Álvarez López, Isabel
Urruticoechea, Ander
Bragado, Paloma
Coleman, Nicholas
Palazón, Asís
Carracedo Pérez, Arkaitz
Gallego Ortega, David
Calvo González, Fernando
Isacke, Clare M.
Caffarel, María M.
Lawrie, Charles
Publication Year :
2022

Abstract

[EN] The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.

Details

Database :
OAIster
Notes :
This work was funded by Spanish Ministry of Science and Innovation - ISCIII (PI15/00623, PI18/00458, PI21/01208, CP18/00076, and FI19/00193); European Regional Development (FEDER) funds; Basque Department of Health (2017111011); Fundación SEOM (Beca SEOM-Font Vella); Fundación Gangoiti; and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patient’s charity Katxalin and from Roche Farma S.A. AMA and AA are funded by Basque Government Doctoral Training Grants. JILV is funded by an AECC PhD Fellowship. FVM is supported by the Career Development Fellowship from the Cancer Institute New South Wales (2019/CDF002). AP’s research is funded by the European Research Council (ERC, ERC-2018-StG 804236-NEXTGEN-IO), and by the Spanish Ministry of Science and Innovation (PID2019-107956RA-I00 and RYC2018-024183-I). AC’s research is supported by the Basque Department of Industry, Tourism and Trade (Elkartek); the MICINN (PID2019-108787RB-I00 [FEDER/EU]; Excellence Network (SAF2016-81975-REDT); European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (GCTRA18006CARR), Vencer el Cáncer Foundation; La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/; and the ERC (Consolidator Grant 819242). CIBERONC was cofunded with FEDER funds and funded by ISCIII. DGO is supported by a Cancer Council NSW project grant (RG18-03) and the National Breast Cancer Foundation Elaine Henry Fellowship (IIRS-21-096). FC is funded by Institute of Cancer Research, Spanish Ministry of Science and Innovation (RYC-2016-20352 and RTI2018-096778-A-I00); Asociacion Española Contra el Cancer (LAB-AECC, LABAE19044CALV); and BBVA Leonardo Awards (IN[19]_BBM_BAS_0076)., English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1328033398
Document Type :
Electronic Resource